1. Scrip

Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC

 
• By Alexandra Shimmings

Merck & Co just keeps clearing the hurdles to checkpoint inhibitor market domination, with EU approval in the key first-line NSCLC indication coming swiftly after the company snuck in an earlier than expected filing in the US for its chemo combination use.

LungCancerCells_1200x675

Merck Sharp & Dohme Ltd. has received an expanded EU approval for its anti-PD1 product Keytruda (pembrolizumab) for first-line use in metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%) with no EGFR or ALK positive tumor mutations. The additional indication brings its EU label into line with that in the US, where it obtained the first-line use approval in October.

It opens up still wider the most important market for the Merck product at a time when its major competitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.